Homocysteine

Homocysteine: A Comprehensive Reference for Nutrition and Natural Health

1. Definition and Biochemical Identity

Homocysteine (Hcy) is a sulfur-containing, non-proteinogenic amino acid derived in methionine metabolism. The American biochemist Vincent du Vigneaud first identified it in 1932 by treating methionine with sulfuric acid. Its structure is similar to cysteine except for one extra carbon atom — hence the name — and subsequent investigation established its role as an intermediate in sulfur amino acid metabolism and transmethylation reactions.

Homocysteine is an amino acid not supplied by the diet; it can be converted into cysteine or recycled back into methionine, an essential amino acid, with the aid of specific B vitamins. It is synthesized exclusively by transmethylation of the essential, diet-derived amino acid methionine — this represents the only way in which homocysteine is produced in humans.

Conversion back to methionine via remethylation, or transsulfuration to cysteine, are the two major metabolic pathways that reduce total homocysteine (tHcy) concentrations in cells and blood. Folic acid acts as a methyl donor, vitamin B12 facilitates methyl group transfer, and vitamin B6 drives the transsulfuration pathway; together, these three B vitamins regulate homocysteine metabolism through complementary and interconnected mechanisms. A third, folate-independent route involves betaine (trimethylglycine), which donates methyl groups to homocysteine via the enzyme betaine-homocysteine methyltransferase (BHMT), converting homocysteine back to methionine.

2. Normal Ranges and Classification of Elevated Levels

Homocysteine levels vary between men and women; the normal range is typically between 5 and 15 µmol/L. Hyperhomocysteinemia is defined as levels exceeding 15 µmol/L. Median fasting total homocysteine levels in adult males are approximately 10 µmol/L.

Hyperhomocysteinemia is observed in approximately 5% of the general population and is associated with increased risk for many disorders. Elevated homocysteine is detected through a fasting blood test measuring total plasma homocysteine, which encompasses free and protein-bound forms as well as homocystine disulfide.

3. Body Systems and Health Areas Involved

3.1 Cardiovascular System

An elevated level of total homocysteine (tHcy) in blood — hyperhomocysteinemia — is a prevalent and strong risk factor for atherosclerotic vascular disease in the coronary, cerebral, and peripheral vessels, and for arterial and venous thromboembolism. The basis for these conclusions is data from approximately 80 clinical and epidemiological studies including more than 10,000 patients. Elevated tHcy confers a graded risk with no threshold, is independent of but may enhance the effect of conventional risk factors, and appears to be a particularly strong predictor of cardiovascular mortality.

Hyperhomocysteinemia increases risk of myocardial infarction, cardiovascular-related morbidity and mortality, peripheral vascular disease, atherosclerosis, coronary heart disease, and cerebrovascular disease. Its seriousness as a risk factor has been equated to hypercholesterolemia and smoking. It has also been shown to produce a multiplicative effect with these and other risk factors such as hypertension.

The proposed mechanisms of vascular harm are several. The most accepted hypotheses about homocysteine's action in cardiovascular disease are direct endothelial and vessel wall damage, oxidative stress generation, and stimulation of a procoagulant and proinflammatory state of blood components. Homocysteine can damage endothelial cells lining the vasculature, allowing plaque formation; simultaneously, it interferes with the vasodilatory effect of endothelial-derived nitric oxide; and it has been found to promote vascular smooth muscle cell hypertrophy — both processes contributing to vessel occlusion.

Despite the robustness of epidemiological associations, the question of causality versus biomarker status remains actively debated. The increased level of homocysteine in plasma is considered to be an independent risk factor for cardio- and cerebrovascular diseases; however, it is still not entirely clear whether homocysteine is a marker or a causative agent of disease. Homocysteine metabolism disturbances and subsequent circulatory buildup are linked to vascular disease risk; on the other hand, B-vitamin treatment has successfully restored average homocysteine concentrations without always producing corresponding decreases in disease risk, and researchers continue to investigate the molecular link between homocysteine equilibrium and disease states.

3.2 Neurological System and Cognitive Health

There is evidence that increased serum homocysteine levels are associated with declining cognitive function and dementia. There is strong evidence that homocysteine is a risk factor not only for cerebrovascular diseases but also for degenerative dementias. A recent consensus statement renewed the importance and role of high homocysteine levels in cognitive decline in several forms of degenerative dementia, such as Alzheimer's disease, although both the impact of homocysteine on specific cognitive functions and the relationship between homocysteine level and non-Alzheimer dementias have been less thoroughly investigated.

An international consensus statement based on the Bradford Hill criteria concluded that elevated plasma total homocysteine is a modifiable risk factor for development of cognitive decline, dementia, and Alzheimer's disease in older persons. In a variety of clinical studies, the relative risk of dementia in elderly people for moderately raised homocysteine ranges from 1.15 to 2.5, and the population-attributable risk ranges from 4.3 to 31%. Intervention trials in elderly individuals with cognitive impairment show that homocysteine-lowering treatment with B vitamins markedly slows the rate of whole and regional brain atrophy and also slows cognitive decline. The findings are consistent with moderately raised plasma total homocysteine (>11 µmol/L) being one of the causes of age-related cognitive decline and dementia.

For every 5 mmol/L increase in homocysteine, the risk of dementia has been estimated to increase by 50%. Conversely, a 3 mmol/L decrease in homocysteine — achievable through folic acid and vitamin B12 treatment — was associated with a 22% reduction in dementia risk, though causality in this context could not be definitively established.

3.3 Skeletal System

Numerous epidemiological reports have established hyperhomocysteinemia as an independent risk factor for osteoporosis-associated fractures. Recent studies report homocysteine to be a newly recognized risk factor for osteoporosis. Elevated homocysteine levels are known to modulate osteoclastogenesis by causing detrimental effects on bone via oxidative stress–induced metalloproteinase-mediated extracellular matrix degradation and decrease in bone blood flow.

In vitro studies have found that homocysteine alters the structure of collagen cross-linking, thus affecting the stability and mineralization of bone tissue. Population studies from Framingham found homocysteine to be a predictor of hip fracture in older individuals. Evidence from cell-line studies suggests that total homocysteine induces apoptosis via caspase and mitochondrial mechanisms, providing evidence that it may contribute to the development of osteoporosis by reducing bone formation.

3.4 Renal System

The imbalance in homocysteine metabolism is implicated in the pathogenesis of diseases including cardiovascular diseases, neurological and psychiatric disorders, chronic kidney disease, bone tissue damage, gastrointestinal disorders, cancer, and congenital defects. Impaired kidney function is itself a major driver of elevated homocysteine, as the kidney is a principal site of homocysteine metabolism; a bidirectional relationship thus exists between hyperhomocysteinemia and chronic kidney disease.

3.5 Reproductive System and Pregnancy

The significance of hyperhomocysteinemia in pregnancy has been investigated in relation to the increased risk of adverse pregnancy outcomes such as small size for gestational age at birth, preeclampsia, recurrent abortions, low birth weight, intrauterine growth restriction, and neural tube defects. One systematic review reported a correlation between elevated homocysteine levels and different complications in pregnancy; in particular, preeclampsia and placental abruption appear to occur more often in pregnant women with serum homocysteine levels from 9.0 to 15.0 µmol/L.

Due to perturbations in methionine metabolism, hyperhomocysteinemia during pregnancy is implicated in adverse outcomes such as neural tube defects, preeclampsia, spontaneous abortion, and premature delivery.

4. Contributing and Associated Factors

4.1 Nutritional Deficiencies

Increased plasma total homocysteine concentrations are found with methionine-rich diets, low vitamin B intake, male gender, age, impaired renal function, and genetically determined defects of the enzymes involved in homocysteine metabolism. Hyperhomocysteinemia arises from a lack of key enzymes or vitamins such as methylenetetrahydrofolate reductase, vitamin B6, and folate, which are involved in homocysteine metabolism.

The B vitamins folate, vitamin B12, and vitamin B6 are the main nutritional determinants of homocysteine concentrations. An inverse relation exists between plasma total homocysteine and circulating folate or vitamin B6 concentrations. Vegans are more vulnerable to vitamin B12 deficiency, which can drive elevated homocysteine, compared to those with moderate consumption of animal dietary sources.

4.2 Genetic Factors: MTHFR and Other Polymorphisms

MTHFR catalyses the irreversible conversion of 5,10-methylenetetrahydrofolate to its active form, 5-methyltetrahydrofolate, a co-substrate for homocysteine remethylation to methionine. Numerous variants of the MTHFR gene have been recognized; the C677T variant is the most extensively studied. The C677T polymorphism, which results in the conversion of valine to alanine at codon 222, is associated with reduced enzyme activity and increased thermolability.

The main genetic determinant of homocysteine concentrations is homozygosity (TT genotype) for the C677T polymorphism in the MTHFR gene, typically found in approximately 10% of Western populations. Individuals homozygous for the TT genotype have significantly elevated homocysteine levels, and the genotype-specific folate threshold level is significantly higher in TT individuals than in those with CC or CT genotypes.

The prevalence of TT homozygosity reaches 25% in China, while it ranges only between 5 and 15% in Europe and North America. MTHFR C677T polymorphism and dietary patterns have interactive effects on hyperhomocysteinemia.

A fairly common genetic polymorphism — the C677T polymorphism of the MTHFR gene — which causes impaired folate metabolism resulting in high homocysteine levels, has been associated with increased risk of coronary artery disease. Hyperhomocysteinemia is an independent risk factor for vascular disease, including coronary disease, and in many instances is due to cystathionine β-synthase (CBS) deficiency.

4.3 Age and Sex

Male sex, older age, and higher BMI are risk factors for hyperhomocysteinemia. Homocysteine concentrations increase with age. The higher baseline levels observed in men partly reflect differences in muscle mass and creatine synthesis, as homocysteine production is proportional to lean body mass turnover.

4.4 Impaired Renal Function

Other causes of elevated homocysteine include low intake or deficiencies of B vitamins, genetic defects, polymorphisms of enzymes involved in homocysteine metabolism, impaired renal function, and lifestyle factors such as smoking and heavy coffee consumption. The kidney is a key site of homocysteine catabolism, and progressive renal impairment consistently elevates plasma homocysteine; elevated creatinine has been identified as a significant independent predictor of hyperhomocysteinemia.

4.5 Drug Interactions

Several commonly used medications interfere with homocysteine metabolism by antagonizing folate or vitamin B12. Long-term metformin use may interfere with vitamin B12 absorption and disrupt folic acid metabolism, reducing levels of these vitamins. This reduction contributes to elevated homocysteine levels and increases the risk of cardiovascular disease and neuropathy. Other recognized drug categories that may raise homocysteine include methotrexate (a folate antagonist), proton pump inhibitors (which reduce B12 absorption over time), anticonvulsants, and nitrous oxide anesthesia, each through distinct mechanisms.

4.6 Body Composition

Increases in total body fat proportion and decreases in lean body mass (LBM) are significantly associated with increases in homocysteine concentration, even after controlling for confounding factors; decreases in LBM were found to predict hyperhomocysteinemia at follow-up in a prospective cohort study.

5. Dietary Factors

5.1 Dietary Patterns Associated with Lower Homocysteine

Several modifiable factors exert a strong effect on homocysteine concentration. These include adequate dietary intake of folate and vitamins B6 or B12, and intake of proteins rich in methionine that help regulate homocysteine biochemical pathways.

Diets rich in fruits, vegetables, whole grains, and legumes — the principal food sources of dietary folate — are broadly associated with lower plasma homocysteine, primarily through their contribution to the body's folate status. Research has shown that a diet rich in whole-grain foods — which are high in betaine — produced a significant increase in plasma betaine concentrations as well as a significant decrease in plasma homocysteine and LDL cholesterol levels in healthy participants over four weeks.

The genetic risk conferred by MTHFR TT homozygosity can be influenced by folate intake, with the highest risk observed at the lowest levels of folate intake.

5.2 High Animal Protein Intake

Because homocysteine is produced exclusively during the metabolism of methionine, diets very high in methionine-rich animal proteins (red meat, certain dairy products) increase the substrate load for homocysteine production. Increased plasma tHcy concentrations are found with methionine-rich diets.

5.3 Saturated Fat Intake

Increased intake of saturated fatty acids is correlated with higher concentrations of total plasma homocysteine; the difference between the extreme quartiles of saturated fat intake was approximately 8.8% in one population study.

6. Lifestyle Factors

6.1 Smoking

The lifestyle factors most strongly associated with plasma total homocysteine level in a population-based sample of 3,025 Dutch adults were smoking (positive association), alcohol drinking, and coffee consumption (positive association). The smoking effect was most prominent in women. Increasing age, male sex, smoking, coffee consumption, high blood pressure, unfavorable lipid profile, high creatinine, and faulty diet are all factors associated with increased homocysteine levels.

6.2 Coffee Consumption

Heavy coffee consumption is known to elevate homocysteine levels. This effect has been documented in multiple epidemiological studies and is thought to be related to compounds in coffee that interfere with vitamin B6 metabolism or to chlorogenic acid impeding folate absorption, though the exact mechanism is not fully established. Notably, not all observational studies find a statistically significant independent association with coffee after adjustment for other lifestyle factors.

6.3 Alcohol

The relationship between alcohol and homocysteine is complex. The lifestyle factors most strongly associated with plasma homocysteine included alcohol drinking, with the alcohol effect most pronounced in men. Heavy chronic alcohol consumption impairs folate absorption and metabolism, and can elevate homocysteine. However, in some observational studies, moderate alcohol intake shows a neutral or slightly inverse association. Alcohol abuse, high coffee intake, and smoking habits are among the unhealthy lifestyle choices that could increase the risk of hyperhomocysteinemia-related pathologies.

6.4 Physical Inactivity

Mild hyperhomocysteinemia can be a result of lifestyle factors including smoking, alcohol consumption, lack of exercise, tobacco, and caffeine use. Scientific attention has shifted toward viewing homocysteine as part of a complex network of modifiable cardiovascular risk factors, where lifestyle modifications — particularly diet, physical activity, smoking cessation, and blood pressure management — have demonstrated synergistic benefits for cardiovascular health.

Data from a large Dutch population-based study indicated that, independently of other lifestyle factors, age, and intake of folate and B vitamin supplements, a change in lifestyle could result in a 0.1- to 1.7-µmol/L change in plasma total homocysteine level, with the authors concluding that lifestyle changes could produce a public-health-relevant change in plasma total homocysteine concentrations.

7. Nutrients and Natural Ingredients: Scientific Evidence

7.1 Folate (Vitamin B9)

A meta-analysis demonstrated that reductions in blood homocysteine levels were greater at higher pretreatment blood homocysteine levels and at lower pretreatment folate concentrations. After standardization for typical Western population values, dietary folic acid reduced homocysteine levels by 25% (95% CI: 23–28%), with similar effects across a daily dosage range of 0.5 to 5 mg.

Daily doses of ≥0.8 mg folic acid are typically required to achieve the maximal reduction in plasma homocysteine concentrations produced by folic acid supplementation.

An inverse relation exists between plasma total homocysteine and circulating folate concentrations, and folic acid supplements of 0.5 mg/day can reduce tHcy levels by approximately 25%.

Evidence quality: Strong. Multiple randomized controlled trials and meta-analyses confirm that folic acid supplementation reliably lowers plasma homocysteine. However, meta-analysis has observed no significant causal relationship between folate supplementation–induced homocysteine reduction and coronary heart disease risk reduction, illustrating that lowering homocysteine biochemically does not automatically translate to hard cardiovascular event prevention.

Personalized strategies — such as using the active form 5-methyltetrahydrofolate (5-MTHF) — could boost effectiveness, especially for those who are genetically predisposed (e.g., MTHFR TT genotype carriers).

7.2 Vitamin B12 (Cobalamin)

Vitamin B12 (mean dose 0.5 mg) produced an additional reduction in blood homocysteine of 7%, beyond the reduction achieved by folic acid alone. Relying on a single vitamin may be insufficient owing to metabolic limitations — for example, the "folic acid trap," in which excess folate can mask vitamin B12 deficiency and impair homocysteine clearance.

Supplementing subjects with 5 mg of folic acid and 250 mg of vitamin B12 for 12 weeks reduced plasma homocysteine levels by 32% in subjects with coronary artery disease.

Evidence quality: Strong for homocysteine lowering. Vitamin B12 supplementation consistently reduces homocysteine, especially in deficient individuals; the effect on clinical outcomes of cardiovascular disease remains unproven in large RCTs.

7.3 Vitamin B6 (Pyridoxine)

Vitamin B6 did not have a significant effect on homocysteine concentrations in the meta-analysis of randomized trials. Vitamin B6 is an essential cofactor for the transsulfuration pathway, catalyzing the conversion of homocysteine to cystathionine via CBS. Its supplementation is most relevant in the context of an already-replete folate and B12 status, or in specific metabolic contexts such as high methionine load. Combined folic acid and oral B6 and B12 supplementation makes a pharmacologically attractive addition for addressing elevated homocysteine.

Evidence quality: Moderate. Although biologically necessary for homocysteine transsulfuration, trials of supplemental B6 alone do not show significant independent homocysteine-lowering, though B6 is included in most combination regimens studied in RCTs.

7.4 Riboflavin (Vitamin B2)

Riboflavin has more recently been identified as a potent modulator of homocysteine specifically in individuals with the MTHFR TT genotype. Evidence suggests that riboflavin supplementation lowers homocysteine levels only among individuals homozygous for the T allele of the MTHFR C677T polymorphism — approximately 15% of the general population — and not in broader populations.

Evidence quality: Moderate but genotype-specific. Riboflavin's homocysteine-lowering effect appears to be clinically meaningful primarily for MTHFR TT carriers; it is not a general-population intervention based on current evidence.

7.5 Betaine (Trimethylglycine, TMG)

Supplementation with betaine decreases plasma homocysteine concentrations substantially in patients with hyperhomocysteinemia. Studies in healthy volunteers show that 6 g/day of betaine lowers plasma homocysteine concentrations by 5% to 20%.

The pooled estimate of effect from a meta-analysis of five randomized controlled trials — all in healthy adult participants supplemented with at least 4 g/day of betaine for between 6 and 24 weeks — was a statistically significant reduction in plasma homocysteine of 1.23 µmol/L (95% CI, approximately −1.x).

Betaine and choline intakes are associated with both fasting and post-methionine-load total homocysteine concentrations, especially in participants with low folate and vitamin B12 status.

A potential limitation is that betaine supplementation may raise LDL and total cholesterol in some populations. Studies in renal patients and in obese individuals on a weight-loss diet suggest that betaine supplementation may raise blood cholesterol, which would counteract any favorable effect on homocysteine.

Betaine is found naturally in most living organisms; it is formed in cells as an oxidation product of choline and can be obtained from foods such as spinach, beets, and wheat products.

Evidence quality: Moderate. Multiple RCTs confirm a modest but statistically significant homocysteine-lowering effect of betaine in healthy adults; effect size is smaller than that of folic acid. Long-term cardiovascular outcomes have not been established.

7.6 Choline

Elevated total homocysteine, a risk factor for many chronic diseases, can be remethylated to methionine by folate; alternatively, it can be metabolized by other one-carbon nutrients such as betaine and its precursor, choline. Total intake of choline plus betaine was inversely associated with total homocysteine, even after adjustment for folate and riboflavin; in multivariate models, homocysteine was 8% lower in the highest quintile of choline plus betaine intake than in the lowest quintile.

Choline and/or betaine supplementation lowers homocysteine levels only in specific populations, such as those with pyridoxine-resistant homocystinuria and hyperhomocysteinemia due to deficient cystathionine β-synthase activity, or after a post-methionine load rise in homocysteine.

Evidence quality: Preliminary for supplemental choline in general populations. Dietary choline from food may contribute modestly to homocysteine regulation through its conversion to betaine, particularly when folate and B12 status are suboptimal.

7.7 Combined B-Vitamin Supplementation

Combined B-vitamin supplementation (folic acid, B6, and B12 together) significantly reduced serum homocysteine levels — with a mean difference of −2.36 µmol/L (95% CI: −3.09 to −1.62) — compared with any single-nutrient regimen in a systematic meta-analysis.

Simple, inexpensive, and nontoxic therapy with folic acid and vitamins B6 and B12 reduces plasma homocysteine levels by approximately 25% to 30%. Meta-analysis evidence proved that vitamin B supplementation effectively reduces homocysteine levels and the risk of stroke and vascular deaths; however, no risk reduction was observed for cardiovascular events more broadly among the vitamin group.

Although combined folic acid and B-vitamin therapy substantially reduces homocysteine levels, results from randomized placebo-controlled clinical trials testing the effect of vitamin therapy on disease outcomes are mixed, but have generally fallen short of expectations.

Evidence quality: Strong for homocysteine lowering; mixed to weak for hard clinical outcomes. The disconnect between biochemical efficacy and cardiovascular event reduction is a major unresolved issue in the field and has led some researchers to question whether the tested intervention populations were appropriate, or whether elevated homocysteine is primarily a biomarker rather than a direct causal agent.

7.8 N-Acetylcysteine (NAC)

NAC is a source of cysteine that can be used in the body to manufacture the important antioxidant compound glutathione. By increasing glutathione production and lowering oxidative stress, it is thought that NAC might help mitigate some toxic effects of excess homocysteine. NAC has been shown to lower homocysteine levels in some studies. The proposed mechanism involves NAC displacing homocysteine from its protein carrier in blood, forming cysteine and NAC disulfide molecules with high renal clearance.

Evidence quality: Preliminary. The number of human trials specifically examining NAC's effect on plasma homocysteine is limited. While mechanistic rationale exists and initial studies are promising, large RCTs establishing dose–response relationships and clinical outcomes are lacking.

7.9 Omega-3 Fatty Acids

A diet rich in long-chain omega-3 fatty acids appeared to reduce homocysteine concentrations only in conjunction with high B-vitamin supplementation in one Norwegian population study. Omega-3 fatty acids are not considered a primary homocysteine-lowering agent, but may have complementary roles when combined with B vitamins.

Evidence quality: Weak and inconsistent as a standalone homocysteine intervention. Omega-3 supplementation alone does not reliably lower homocysteine; any observed effects appear to be context-dependent.

8. Traditional Uses — Historical and Ethnobotanical Context

The concept of "homocysteine" as a specific clinical target did not exist in traditional medical systems. Traditional herbalism and nutrition systems predate the biochemical discovery of homocysteine by centuries and therefore do not contain direct references to it. However, several nutritional practices within traditional systems align, in retrospect, with what modern science recognizes as homocysteine-modulating nutrition:

• Leafy green vegetables (Ayurveda, Traditional Chinese Medicine, Mediterranean diets): The emphasis on dark leafy greens — including spinach, fenugreek, and various culinary herbs — in many traditional diets represents a historically high-folate dietary pattern now recognized to directly support homocysteine metabolism. In Ayurvedic texts, preparations involving fresh green vegetables and legumes were described as purifying to the blood and supportive of longevity, consistent with their folate content.
• Beets (Beta vulgaris): Consumed across European, Eastern Mediterranean, and Central Asian traditions both as food and medicine — in the form of beet juice, soups, and fermented preparations — beets are now understood to be among the richest natural dietary sources of betaine. Traditional uses included beet as a liver tonic, blood purifier, and digestive aid, though no traditional system explicitly connected this to homocysteine metabolism.
• Whole grains and wheat germ: Traditional diets in many cultures, including those of Central Asia and the Middle East, featured whole-grain breads and wheat preparations. Wheat bran and wheat germ are concentrated sources of betaine, though this connection to homocysteine modulation was not a part of traditional rationale, which instead emphasized digestive and nutritive properties.
• Animal liver and organ meats: Consumed widely across global traditional cuisines as a nutrient-dense food for anemia, weakness, and convalescence, organ meats — particularly liver — are the richest natural sources of both vitamin B12 and folate. Traditional healers across diverse cultures prescribed liver for conditions of pallor and exhaustion long before the discovery of these specific vitamins.

It is important to state clearly: no traditional medical system formally identified, named, or specifically targeted elevated homocysteine. The above traditional practices are noted only for their retrospective nutritional alignment with what modern biochemistry has since elucidated. Any direct claim that traditional medicine "treated" hyperhomocysteinemia would be anachronistic and inaccurate.

9. Scientific Evidence on Dietary Sources and Food Patterns

Foods naturally rich in the homocysteine-relevant nutrients include:

• Folate: Dark leafy greens (spinach, romaine lettuce, kale), legumes (lentils, chickpeas, black beans), avocado, fortified cereals, and liver are primary dietary sources. Dietary intake of folate is a major determinant of blood homocysteine concentrations.
• Vitamin B12: Found almost exclusively in animal products — meat, fish, shellfish, eggs, and dairy. Vegans are more vulnerable to vitamin B12 deficiency than those with moderate consumption of animal products.
• Vitamin B6: Found in poultry, fish, potatoes, starchy vegetables, and non-citrus fruit. Pyridoxal-5'-phosphate (PLP) is the biologically active form.
• Betaine: Betaine is formed in cells as an oxidation product of choline and can be obtained from foods such as spinach, beets, and wheat products.
• Riboflavin: Found in dairy products, eggs, lean meats, and fortified cereals; particularly relevant for homocysteine regulation in MTHFR TT carriers.

10. Evidence Gaps and Research Limitations

The homocysteine field is characterized by a persistent and unresolved tension. While approximately 80 clinical and epidemiological studies including more than 10,000 patients form the basis for establishing elevated homocysteine as a risk factor, large-scale intervention trials have not reliably converted homocysteine-lowering into proportionate reductions in clinical events. These results have led some researchers to question homocysteine monitoring in clinical management; however, these trials generally included patients with only mildly elevated homocysteine levels and have not addressed several clinical scenarios in which homocysteine monitoring and treatment may still be relevant.

Although interventional studies analyzing B-vitamin supplementation for prevention of homocysteine-related cognitive decline have shown limited results, promotion of healthy lifestyle, screening of high-risk subjects, and earlier therapeutic approaches — before neurological damage has occurred — could yield better outcomes.

Key remaining evidence gaps include: (1) identifying which patient subgroups benefit most from homocysteine-lowering strategies; (2) establishing optimal threshold targets beyond the conventional 15 µmol/L clinical cutoff; (3) understanding the interaction between genetic variants and nutritional interventions; and (4) determining whether active vitamin forms (5-MTHF, methylcobalamin, pyridoxal-5'-phosphate) confer clinical advantages over standard forms. Further studies are warranted to identify optimal therapeutic targets and to delineate patient subgroups most likely to benefit from tailored supplementation strategies.

References

• Stehouwer et al. (1999). Homocysteine and risk of cardiovascular disease. Semin Thromb Hemost. PubMed
• Antoniades et al. (2005). Metabolism of homocysteine and its relationship with cardiovascular disease. Curr Med Chem. PubMed
• Zawada et al. (2016). The Molecular and Cellular Effect of Homocysteine Metabolism Imbalance on Human Health. Int J Mol Sci. PMC
• Azzini E et al. Hyperhomocysteinemia. StatPearls. NCBI Bookshelf (NIH)
• Selhub J et al. (2009). The Treatment of Hyperhomocysteinemia. Annu Rev Nutr. PMC (NIH)
• Clarke R et al. (1991). Hyperhomocysteinemia: An Independent Risk Factor for Vascular Disease. N Engl J Med.
• Refsum H et al. (1998). Homocysteine and cardiovascular disease. Annu Rev Med. PubMed
• Perła-Kaján J et al. (2019). Hyperhomocysteinemia as a Risk Factor and Potential Nutraceutical Target for Certain Pathologies. Front Nutr. PMC
• Li D et al. (2021). Prevalence and risk factors for hyperhomocysteinemia: a population-based cross-sectional study from Hunan, China. Front Nutr. PMC
• Gupta A et al. (2011). Genetics of homocysteine metabolism and associated disorders. Biochim Biophys Acta. PMC
• Borowczyk K et al. (2024). The Implication of a Polymorphism in the Methylenetetrahydrofolate Reductase Gene in Homocysteine Metabolism and Related Civilisation Diseases. Int J Mol Sci. PMC
• Wu M et al. (2021). Methylenetetrahydrofolate Reductase Gene C677T Polymorphism–Dietary Pattern Interaction on Hyperhomocysteinemia. Front Nutr. PMC
• Li J et al. (2017). Influence of food groups on plasma total homocysteine for specific MTHFR C677T genotypes in Chinese population. Sci Rep. PMC
• Cho H et al. (2005). Gene-nutrition interactions in coronary artery disease: MTHFR C677T polymorphism and folate and homocysteine status. J Korean Med Sci. PubMed
• Ujan SA et al. (2023). Homocysteine, Vitamin B12 and Folate: Possible Risk Factors in the Progression of Chronic Heart and Kidney Disorders. J Clin Med. PMC
• Lonn E et al. (2006). HOPE-2 Trial Rationale and Design. Can J Cardiol. PMC
• Tan L et al. (2025). Combined B-vitamin supplementation on homocysteine and vascular outcomes in coronary heart disease: a meta-analysis. PMC
• Kataria N et al. (2021). Effect of Vitamin B6, B9, and B12 Supplementation on Homocysteine Level and Cardiovascular Outcomes in Stroke Patients: A Meta-Analysis. Cureus. PMC
• Homocysteine Lowering Trialists' Collaboration (2000). Vitamin supplements and cardiovascular risk: review of the randomized trials. J Cardiovasc Risk. PubMed
• Homocysteine Lowering Trialists' Collaboration (2005). Dose-dependent effects of folic acid on blood concentrations of homocysteine: a meta-analysis of randomized trials. Am J Clin Nutr.
• Olthof MR, Verhoef P (2013). Betaine supplementation decreases plasma homocysteine in healthy adult participants: a meta-analysis. Nutr Rev. PMC
• Melse-Boonstra A et al. (2014). Plasma homocysteine, dietary B vitamins, betaine, and choline and risk of peripheral artery disease. Atherosclerosis. PMC
• Chiuve SE et al. (2007). The association between betaine and choline intakes and plasma homocysteine concentrations in women. Am J Clin Nutr. PMC
• Zhao G et al. (2023). Betaine as a Functional Ingredient: Metabolism, Health-Promoting Attributes, Food Sources, Applications and Analysis Methods. Foods. PMC
• Patterson C et al. (2004). Homocysteine and cognitive function in elderly people. CMAJ. PMC
• Oulhaj A et al. (2022). Homocysteine, Cognitive Functions, and Degenerative Dementias: State of the Art. J Alzheimers Dis. PMC
• Smith AD et al. (2024). Deficiencies in one-carbon metabolism led to increased neurological disease risk and worse outcome: homocysteine is a marker of disease state. PMC
• Panza F et al. (2021). Elevated Blood Homocysteine and Risk of Alzheimer's Dementia: An Updated Systematic Review and Meta-Analysis. PMC
• Smith AD et al. (2018). Homocysteine and Dementia: An International Consensus Statement. J Alzheimers Dis. PubMed
• Ostrakhovitch EA, Tabibzadeh S (2016). Homocysteine in Renal Injury. Adv Clin Chem. PMC
• Thakkar R et al. (2017). Homocysteine as a Pathological Biomarker for Bone Disease. J Cell Physiol. PMC
• Behera J et al. (2014). The role of homocysteine in bone remodeling. Clin Chem Lab Med. PMC
• Brosnan EM et al. (2009). The relation of plasma homocysteine to radiographic knee osteoarthritis. Osteoarthritis Cartilage. PMC
• Azzini E et al. (2020). Homocysteine: Its Possible Emerging Role in At-Risk Population Groups. Int J Mol Sci. PMC
• Nayal B et al. (2012). The influence of homocysteine and oxidative stress on pregnancy outcome. J Obstet Gynaecol. PMC
• Blom HJ, Smulders Y (2011). Overview of homocysteine and folate metabolism, with special references to cardiovascular disease and neural tube defects. J Inherit Metab Dis. PMC
• de Bree A et al. (2001). Lifestyle factors and plasma homocysteine concentrations in a general population sample. Am J Epidemiol. PubMed
• Kim OY et al. (2013). Changes in Body Composition Predict Homocysteine Changes and Hyperhomocysteinemia in Korea. J Nutr Biochem. PMC
• Ganguly P, Alam SF (2015). Role of homocysteine in the development of cardiovascular disease. Nutr J. PMC
• Liberale L et al. (2025). Homocysteine in the Cardiovascular Setting: What to Know, What to Do, and What Not to Do. PMC
• Chen X et al. (2025). Effects of folic acid with vitamin B12/vitamin B6 intervention on serum homocysteine metabolism and complications in patients with type 2 diabetes: a systematic review and meta-analysis. PMC
• Zuhra K et al. (2020). Cysteine and homocysteine as biomarker of various diseases. Food Sci Nutr. PMC
• Lim JH et al. (2010). Major Determinants of Serum Homocysteine Concentrations in a Korean Population. Clin Chem Lab Med. PMC